1254 related articles for article (PubMed ID: 28486906)
1. Safety and Toxicological Considerations of Nanomedicines: The Future Directions.
Patel P; Shah J
Curr Clin Pharmacol; 2017; 12(2):73-82. PubMed ID: 28486906
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in green nanoparticulate systems for drug delivery: efficient delivery and safety concern.
Lam PL; Wong WY; Bian Z; Chui CH; Gambari R
Nanomedicine (Lond); 2017 Feb; 12(4):357-385. PubMed ID: 28078952
[TBL] [Abstract][Full Text] [Related]
3. Preclinical hazard evaluation strategy for nanomedicines.
Siegrist S; Cörek E; Detampel P; Sandström J; Wick P; Huwyler J
Nanotoxicology; 2019 Feb; 13(1):73-99. PubMed ID: 30182784
[TBL] [Abstract][Full Text] [Related]
4. A review of the current scientific and regulatory status of nanomedicines and the challenges ahead.
Hock SC; Ying YM; Wah CL
PDA J Pharm Sci Technol; 2011; 65(2):177-95. PubMed ID: 21502077
[TBL] [Abstract][Full Text] [Related]
5. Evaluating Nanomedicines: Obstacles and Advancements.
Swierczewska M; Crist RM; McNeil SE
Methods Mol Biol; 2018; 1682():3-16. PubMed ID: 29039088
[TBL] [Abstract][Full Text] [Related]
6. Nanotechnology and nanomedicine: going small means aiming big.
Teli MK; Mutalik S; Rajanikant GK
Curr Pharm Des; 2010 Jun; 16(16):1882-92. PubMed ID: 20222866
[TBL] [Abstract][Full Text] [Related]
7. Herbal nanomedicines: Recent advancements, challenges, opportunities and regulatory overview.
Teja PK; Mithiya J; Kate AS; Bairwa K; Chauthe SK
Phytomedicine; 2022 Feb; 96():153890. PubMed ID: 35026510
[TBL] [Abstract][Full Text] [Related]
8. A Safe-by-Design Strategy towards Safer Nanomaterials in Nanomedicines.
Yan L; Zhao F; Wang J; Zu Y; Gu Z; Zhao Y
Adv Mater; 2019 Nov; 31(45):e1805391. PubMed ID: 30701603
[TBL] [Abstract][Full Text] [Related]
9. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine.
Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B
Br J Ophthalmol; 2014 Apr; 98(4):427-31. PubMed ID: 24246373
[TBL] [Abstract][Full Text] [Related]
10. Nanomedical engineering: shaping future nanomedicines.
Luo D; Carter KA; Lovell JF
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2015; 7(2):169-88. PubMed ID: 25377691
[TBL] [Abstract][Full Text] [Related]
11. Nanomaterials meet zebrafish: Toxicity evaluation and drug delivery applications.
Jia HR; Zhu YX; Duan QY; Chen Z; Wu FG
J Control Release; 2019 Oct; 311-312():301-318. PubMed ID: 31446084
[TBL] [Abstract][Full Text] [Related]
12. Nanotherapeutics: An insight into healthcare and multi-dimensional applications in medical sector of the modern world.
Prasad M; Lambe UP; Brar B; Shah I; J M; Ranjan K; Rao R; Kumar S; Mahant S; Khurana SK; Iqbal HMN; Dhama K; Misri J; Prasad G
Biomed Pharmacother; 2018 Jan; 97():1521-1537. PubMed ID: 29793315
[TBL] [Abstract][Full Text] [Related]
13. Lysosomal nanotoxicity: Impact of nanomedicines on lysosomal function.
Uzhytchak M; Smolková B; Lunova M; Frtús A; Jirsa M; Dejneka A; Lunov O
Adv Drug Deliv Rev; 2023 Jun; 197():114828. PubMed ID: 37075952
[TBL] [Abstract][Full Text] [Related]
14. Do nanomedicines require novel safety assessments to ensure their safety for long-term human use?
Hoet P; Legiest B; Geys J; Nemery B
Drug Saf; 2009; 32(8):625-36. PubMed ID: 19591528
[TBL] [Abstract][Full Text] [Related]
15. Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology.
Oberdörster G
J Intern Med; 2010 Jan; 267(1):89-105. PubMed ID: 20059646
[TBL] [Abstract][Full Text] [Related]
16. Emerging nanomedicines for early cancer detection and improved treatment: current perspective and future promise.
Bharali DJ; Mousa SA
Pharmacol Ther; 2010 Nov; 128(2):324-35. PubMed ID: 20705093
[TBL] [Abstract][Full Text] [Related]
17. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
[TBL] [Abstract][Full Text] [Related]
18. High drug-loading nanomedicines: progress, current status, and prospects.
Shen S; Wu Y; Liu Y; Wu D
Int J Nanomedicine; 2017; 12():4085-4109. PubMed ID: 28615938
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicines as cancer therapeutics: current status.
Akhter S; Ahmad I; Ahmad MZ; Ramazani F; Singh A; Rahman Z; Ahmad FJ; Storm G; Kok RJ
Curr Cancer Drug Targets; 2013 May; 13(4):362-78. PubMed ID: 23517593
[TBL] [Abstract][Full Text] [Related]
20. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications.
Fadeel B; Garcia-Bennett AE
Adv Drug Deliv Rev; 2010 Mar; 62(3):362-74. PubMed ID: 19900497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]